ZIOP


ZIOPHARM Oncology Inc. (ZIOP) Announces Updated Phase 1 Results in GBM

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced updated results from its Phase 1 multicenter study of Ad-RTS-hIL-12 + veledimex including the 20 mg expansion cohort …

H.C. Wainwright Initiates Buy on ZIOPHARM Oncology Inc. (ZIOP); Sees 53% Upside for the Stock

In a research report released Thursday, H.C.

ZIOPHARM Oncology Inc. (ZIOP) Shares Rose 10% Following Positive Meeting with the FDA

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shareholders woke up to a nice 10% pop in the value of their shares, after the drug maker announced the …

Griffin Commends ZIOPHARM Oncology Inc. (ZIOP) Following Suspension Of Breast Cancer Program

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has indicating the firm will be shifting its R&D pipeline, centering its IL-12 gene therapy program on glioblastoma following …

Company Update (NASDAQ:ZIOP): ZIOPHARM Oncology Inc. Announces 4Q:16 Financial Results and Provides Update on Recent Activities

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced financial results for the fourth quarter ended December 31, 2016, and provided an update on the Company’s recent …

Griffin Lifts Price Target on ZIOPHARM Oncology Inc. (ZIOP) Ahead of Groundbreaking 2017

Griffin analyst Keith Markey sees golden prospects ahead for ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), particularly taking into account the seven clinical trials the firm has …

Company Update (NASDAQ:ZIOP): ZIOPHARM Oncology Inc. And Intrexon Corp To Collaborate With NCI

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) and Intrexon Corp (NYSE:XON) announced the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer …

Stock Update (NASDAQ:ZIOP): ZIOPHARM Oncology Inc. Reports Third Quarter 2016 Financial Results and Provides Update on Recent Activities

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced financial results for the third quarter ended September 30, 2016, and provided an update on the Company’s recent activities.

Griffin Pounds the Table on ZIOPHARM Oncology Inc. (ZIOP)

Griffin analyst Keith Markey was out pounding the table on ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), reiterating a Buy rating and price target of $21.

Stock Update (NASDAQ:ZIOP): ZIOPHARM Oncology Inc. Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced financial results for the second quarter ended June 30, 2016, and provided an update on the Company’s recent activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts